Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABEONASDAQ:BYSINASDAQ:CYADNASDAQ:SIOX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$3.41-53.7%$7.49$2.83▼$9.01$93.26M1.49400,321 shs5.50 million shsBYSIBeyondSpring$2.29+8.5%$2.37$0.65▼$4.00$89.13M0.14188,369 shs112,151 shsCYADCelyad Oncology$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsSIOXSio Gene Therapies$0.48+1.7%$0.46$0.25▼$0.50N/A1.14N/A40,400 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-2.77%-3.66%-3.29%+51.13%+128.57%BYSIBeyondSpring+10.47%+19.89%-32.37%+134.97%+95.37%CYADCelyad Oncology0.00%0.00%0.00%0.00%-6.25%SIOXSio Gene Therapies0.00%0.00%0.00%+22.63%+15.49%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics3.4912 of 5 stars3.51.00.04.51.11.70.6BYSIBeyondSpring0.0033 of 5 stars0.00.00.00.00.02.50.0CYADCelyad OncologyN/AN/AN/AN/AN/AN/AN/AN/ASIOXSio Gene TherapiesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics3.00Buy$36.00955.72% UpsideBYSIBeyondSpringN/AN/A$1.25-45.41% DownsideCYADCelyad OncologyN/AN/AN/AN/ASIOXSio Gene TherapiesN/AN/AN/AN/ACurrent Analyst RatingsLatest CYAD, BYSI, SIOX, and ABEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024ABEOAbeona TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$36.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M26.65N/AN/A$0.60 per share5.68BYSIBeyondSpring$1.35M66.02N/AN/A($0.36) per share-6.36CYADCelyad Oncology$110K144.65N/AN/A$0.20 per share3.00SIOXSio Gene TherapiesN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$54.19M-$2.58N/AN/AN/AN/A-280.58%-76.90%5/9/2024 (Estimated)BYSIBeyondSpring-$33.28MN/A0.00∞N/AN/AN/AN/AN/ACYADCelyad Oncology-$9.14MN/A0.00∞N/AN/AN/AN/AN/ASIOXSio Gene Therapies-$71.89MN/A0.00∞N/AN/AN/AN/AN/ALatest CYAD, BYSI, SIOX, and ABEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/23/2024N/AABEOAbeona TherapeuticsN/A-$0.56-$0.56N/AN/AN/A3/18/2024Q4 2023ABEOAbeona Therapeutics-$0.51-$0.64-$0.13-$0.64N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/ACYADCelyad OncologyN/AN/AN/AN/AN/ASIOXSio Gene TherapiesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona TherapeuticsN/A4.154.15BYSIBeyondSpringN/AN/AN/ACYADCelyad OncologyN/AN/AN/ASIOXSio Gene TherapiesN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%BYSIBeyondSpring40.29%CYADCelyad OncologyN/ASIOXSio Gene TherapiesN/AInsider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.30%BYSIBeyondSpring29.31%CYADCelyad Oncology0.94%SIOXSio Gene Therapies3.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona TherapeuticsN/A27.35 million25.91 millionOptionableBYSIBeyondSpring7338.92 million27.52 millionOptionableCYADCelyad Oncology9526.52 million26.28 millionNot OptionableSIOXSio Gene Therapies12N/AN/ANo DataCYAD, BYSI, SIOX, and ABEO HeadlinesSourceHeadlineGene therapy and the germlinenature.com - April 22 at 11:05 AMGene Therapy for Parkinson's Diseasemedscape.com - March 31 at 1:50 AMSio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Sharefinance.yahoo.com - February 2 at 7:47 AMSio Gene Therapies Inc SIOXmorningstar.com - November 22 at 2:04 PMTwo Promising Gene Therapy Stocks Tackling Eye Diseasethestreet.com - November 1 at 5:29 PMGene Therapy News and Researchnews-medical.net - October 28 at 10:40 AMGene Therapy for Erectile Dysfunctionmedscape.com - October 23 at 7:00 PMIn Mice, Gene Therapy Helps Restore Movement After Spinal Cord Injurysiouxcityjournal.com - September 27 at 3:06 PMRetroviral Vectors for Gene Therapymedscape.com - September 18 at 4:21 PMSio Gene Therapies (NASDAQ: AXGT)fool.com - July 19 at 2:34 AMRoivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billionfinance.yahoo.com - July 13 at 7:44 PMGene Therapy in a Patient with Sickle Cell Diseasenejm.org - June 20 at 10:04 PMGene Therapy for Rheumatoid Arthritismedscape.com - June 12 at 11:10 PMA gene therapy shot might keep cats from getting pregnant without being spayedsciencenews.org - June 12 at 6:10 PMA new gene therapy could be a game-changer for patients with severe anemia. The cost? $2.8 million.nbcnews.com - May 23 at 4:21 PMSio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Resultsfinance.yahoo.com - February 14 at 8:17 AMSIOX Sio Gene Therapies Inc.seekingalpha.com - January 26 at 5:44 PMSio Gene Therapies to dissolve after years of setbacksbiopharmadive.com - December 15 at 2:28 PMSio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolutionfinance.yahoo.com - December 14 at 6:35 PMFollowing layoffs, gene therapy firm leaves Durhambizjournals.com - November 10 at 3:59 PMSio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Resultsfinance.yahoo.com - November 10 at 7:26 AMSio Gene Therapies (NASDAQ:SIOX) Will Have To Spend Its Cash Wiselyfinance.yahoo.com - October 31 at 1:26 PMSio Gene Therapies Announces Fiscal First Quarter 2022 Financial Resultsfinance.yahoo.com - August 11 at 5:41 PMSio Gene Therapies Inc. (SIOX)uk.finance.yahoo.com - August 5 at 9:37 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAbeona TherapeuticsNASDAQ:ABEOAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.BeyondSpringNASDAQ:BYSIBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.Celyad OncologyNASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Sio Gene TherapiesNASDAQ:SIOXSio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.